LAVA Therapeutics Up 7% After Orphan Drug Designation - (Morningstar via NewsPoints Desk)

  • Shares of LAVA Therapeutics were up 7% on Wednesday after the FDA granted the company’s potential treatment of chronic lymphocytic leukemia an orphan drug designation, as reported by Morningstar.

  • The FDA lists the generic name of the treatment as immunoglobulin VHH fragment-linker-VHH fragment, anti-CD1d and anti-[Vdelta2 T-cell receptor], humanized monoclonal antibody.

To read more NewsPoints articles, click here.